Apixaban cohort Dabigatran cohort Apixaban cohort Rivaroxaban
cohort		 Dabigatran cohort Rivaroxaban
cohort
N/Mean %/SD N/Mean %/SD N/Mean %/SD N/Mean %/SD N/Mean %/SD N/Mean %/SD
Sample size 2373 100% 2373 100% 7180 100% 7180 100% 2,617 100% 2,617 100%
Age 69.0 9.6 69.0 9.6 69.8 9.7 69.7 9.7 68.1 9.9 67.9 10.0
Gender
Male 1173 49.4% 1175 49.5% 3348 46.6% 3382 47.1% 1336 51.1% 1310 50.1%
US geographic region*
Northeast 442 18.6% 436 18.4% 1154 16.1% 1141 15.9% 504 19.3% 535 20.4%
North Central 651 27.4% 628 26.5% 1879 26.2% 1897 26.4% 687 26.3% 681 26.0%
South 950 40.0% 997 42.0% 3252 45.3% 3223 44.9% 1083 41.4% 1069 40.8%
West - - - - 877 12.2% 898 12.5% - - - -
Other - - - - 18 0.3% 21 0.3% - - - -
Race (only for Humana and Medicare)
White 1497 87.4% 1496 87.3% 4681 88.4% 4671 88.2% 1532 87.1% 1528 86.9%
Black 137 8.0% 148 8.6% 408 7.7% 408 7.7% 150 8.5% 157 8.9%
Other 79 3.3% 69 2.9% 208 2.9% 218 3.0% 76 2.9% 73 2.8%
Baseline comorbidity
Deyo-Charlson Comorbidity Index 3.9 2.9 3.8 2.9 4.1 3.0 4.1 3.0 3.7 2.9 3.8 2.9
1|2|3|4|5|6|7|8